Tagged with B

Hong Kong Ingrid Reinli, general manager of the European Chamber of Commerce in Hong Kong, discusses the chamber´s strategic priorities and how it serves to unify the European presence in the market. She also reflects on the relationship between Hong Kong and the many European countries investing into the region. Why did…

UK Thomas Broeer, managing director UK and Ireland for Aurobindo, has been at the helm of Aurobindo’s UK subsidiary, Milpharm Limited for almost two years and here discusses the UK market’s strengths, the potential impact of Brexit on the pharmaceutical industry and the pricing structures in place in the UK.  …

Belun Technology Lydia Leung, CEO of Belun Technology, introduces us to the start-up´s flagship product, the Belun Ring. She also discusses the impact that Artificial Intelligence (AI) and preventative care can have on the healthcare industry in Hong Kong. Having been in a government research institute for ten years before joining Belun…

Hong Kong Merck Hong Kong’s Hee-sun Lee gives her first impressions of the Hong Kong market, her main priorities, upcoming product launches and tapping into the territory’s R&D ecosystem. Hee-sun, having joined Merck Pharmaceutical Hong Kong in February 2018 from the South Korean affiliate, what are your first impressions of the market…

UK Three years into his role as general manager of Sobi’s UK and Republic of Ireland operations, Neil Dugdale introduces the scope of operations of the Swedish rare disease player to our audience, highlighting the company’s unique positioning in working closely with patient groups to drive forward better understanding of unmet…

UK One notable quirk of the British life sciences ecosystem is the importance of its not-for-profit sector. Indeed, in 2017, UK charities poured GBP 1.6 billion (USD 2.1 billion) into medical research; more than both the Medical Research Council (MRC) and the National Institute for Health Research (NIHR). Simon Gillespie, chief…

UK Heading FUJIFILM Diosynth Biotechnologies’ operations globally, Steve Bagshaw speaks out about the excellence of science in the UK and how it fits the company’s plans to build up a solid presence in the development and manufacturing of new advanced treatments. He further explains how the company has been able to…

Turkey Hakan Koçak, CEO–general manager of Koçak Farma, a company with 47 years in the pharmaceutical industry and the biggest production facility in Turkey, gives a thorough insight into Koçak Farma’s background, with their ground-breaking biosimilars as the leaders in the area of oncology with 85 products approved in Turkey, in…

UK Chief Executive since 2011, Peter Coleman introduces Cobra Biologics and highlights challenges both domestically and globally in the biotech space for CDMOs; he addresses funding opportunities within the public and private sector and Cobra Biologics’ ambitious plans for 2022. Can you please introduce Cobra Biologics to our international readers? “The…

Cyprus Nicos Karoullas, managing director at Pharmaceutical Trading, explains the unique story of the company created by his father in Famagusta and its life-changing relocation to Larnaca. He also showcases the important of business partnerships in the island and how they are the key factor to grow a business. Pharmaceutical Trading…

UK Adaptimmune, a British-based biotech company born out of the University of Oxford has a solid research base in the UK and manufactures its T-Cells in the US. Its CEO, James Noble, shares Adaptimmune’s story and explains why regulatory support is essential in a field as complex and novel as T-Cell…

Hong Kong Ir. Prof. Andros Chan, president of the Hong Kong Medical and Healthcare Device Industry Association (HKMHDIA), introduces the organization’s mandate, the emerging trends in Hong Kong medtech, and the impact of the Greater Bay Area initiative on his industry. Andros, as a founding member of the HKMHDIA, could you share…